- A phase III study for Johnson & Johnson's (JNJ) Paliperidone Palmitate 3-month formulation for schizophrenia has been stopped early due to the drug's effectiveness in delaying relapse when compared with a placebo.
- The data is now set to be unblinded.
- J&J unit Janssen, which developed the drug, plans to file for FDA approval of the treatment by the end of the year. (PR)
Trial for J&J schizophrenia drug stopped early due to efficacy
From other sites
at CNBC.com (Fri, 8:17AM)
Video at CNBC.com (Wed, 3:37PM)
Video at CNBC.com (Wed, 1:55PM)
at CNBC.com (May 20, 2015)
Video at CNBC.com (May 20, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs